Defining asthma control
How do patient perceptions of asthma control differ from guideline definitions?
This browser is no longer supported.
To provide you with the best possible experience, we kindly ask you to switch to a supported browser:
For inhaled corticosteroids, measuring cortisol suppression is the most sensitive and easily monitored biomarker of adverse systemic effects.1
The maximum ICS dose licensed with Relvar is substantially lower than that estimated for 20% cortisol suppression.*1 In fact, geometric mean 24-hour serum cortisol has been shown to be similar after 42 days of treatment with Relvar to that seen with placebo.2
This graph has been independently created by GSK from the original data. The same results were first published in Daley-Yates PT. Br J Clin Pharmacol 2015;80:372–380.
Fluticasone furoate is not licensed for use as monotherapy.
This graph has been independently created by GSK from the original data. The same results were first published in Allen A, et al. Clin Respir J 2013;7:397–406.
From educational videos to podcasts, Breathing Space is a GSK initiative designed to share the latest thinking on lung health and provide a space for pulmonologists and other respiratory specialists to gather insights and explore best practice.
*Indirect data comparison based on PK/PD modelling. The model uses 20% cortisol suppression as the lowest boundary of detectable systemic exposure for corticosteroids, serving as a cut-off point above which the adverse events of corticosteroids become more likely.1
DPI, dry powder inhaler; FF, fluticasone furoate; HFA, hydrofluoroalkane; HPA, hypothalamicpituitary-adrenal; ICS, inhaled corticosteroid; LABA, long-acting β2-agonist; OD, once daily; PD, pharmacodynamic; PK, pharmacokinetic.
RELVAR Ellipta was created in collaboration with
Adverse events should be reported directly to the Health Products Regulatory Authority (HPRA) on their website: www.hpra.ie . Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.
Relvar is a registered trademark of the GlaxoSmithKline group of companies
A.G. Last updated: May 2021 PM-IE-FFV-WCNT-210005